This is a preview of subscription content, log in via an institution to check access.
Reference
Rana D, et al. Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide. PharmacoEconomics-Open : 10 Nov 2021. Available from: URL: https://doi.org/10.1007/s41669-021-00307-1
Rights and permissions
About this article
Cite this article
Similar costs for mCRPC patients treated with abiraterone vs enzalutamide in Scotland. PharmacoEcon Outcomes News 892, 22 (2021). https://doi.org/10.1007/s40274-021-08217-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-08217-z